Abstract：
Although lymphatic filariasis and onchocerciasis have been targeted for global elimination, these helminth infections are still a major public health problem across the tropics and subtropics. Despite decades of research, treatment options remain limited and drugs that completely clear the infections, and can be used on a large scale, are still unavailable. In the present review we discuss the strengths and weaknesses of currently available treatments and new ones in development. Novel candidates (corallopyronin A, DNDi-6166, emodepside, and oxfendazole) are currently moving through (pre)clinical development, while the development of two candidates (AWZ1066S and ABBV-4083/flubentylosin) was recently halted. The preclinical R&D pipeline for filarial infections continues to be limited, and recent setbacks highlight the importance of continuous drug discovery and testing.
摘要：
尽管淋巴丝虫病和盘尾丝虫病已成为全球消除的目标，这些蠕虫感染仍然是整个热带和亚热带地区的主要公共卫生问题。尽管经过几十年的研究,治疗选择仍然有限，完全清除感染的药物，可以大规模使用，仍然不可用。在本综述中，我们讨论了当前可用的治疗方法和正在开发的新治疗方法的优缺点。新型候选物(corallopyroninA，DNDi-6166,emodepside,和奥芬达唑）目前正在进行（临床前）开发，而最近停止了两种候选物（AWZ1066S和ABBV-4083/flubentylosin）的开发。丝虫感染的临床前研发渠道仍然有限，最近的挫折凸显了持续药物发现和测试的重要性。
